Skip to content
Skin Over SteelGet support now

The workup · Checklists

What gets drawn, and why

Established

Three checklists for three conversations. Each line names a test, says in one sentence what it is for, and points to where that comes from. Take the list to your clinician, or use it to check that the panel you were handed covers what it should.

A checklist, not an order set and not a diagnosis. Which tests you need, and what the results mean for you, is a clinician's call. Read your labs explains each marker.

Before a testosterone conversation

What a clinician needs to tell whether testosterone is low, why, and whether therapy would be safe to start.

  • Total testosterone, early morning, on two separate days

    The diagnosis needs symptoms plus a consistently low level. One draw is not enough.

    Source: Endocrine Society 2018

  • SHBG, with albumin

    Lets free testosterone be estimated when the total is borderline or SHBG is unusually high or low.

    Source: Endocrine Society 2018

  • LH and FSH

    Separates a testicular cause from a pituitary one, which changes the rest of the workup.

    Source: Endocrine Society 2018

  • Prolactin

    High prolactin can suppress testosterone. Checked when LH and FSH point to a pituitary cause.

    Source: Endocrine Society 2018

  • Hematocrit (CBC)

    The baseline every later draw on therapy is compared against.

    Source: Endocrine Society 2018

  • PSA

    A prostate baseline for men who choose prostate monitoring with their clinician: ages 55 to 69, or 40 to 69 at increased risk.

    Source: Endocrine Society 2018

  • Estradiol

    Often on a baseline panel. Read in context, not chased to a number.

    Source: Read your labs

Have total testosterone and SHBG already? Estimate free testosterone.

On testosterone therapy

The monitoring that keeps prescribed therapy safe. Your prescriber orders these and reads them; this is so you know what should be happening.

  • Testosterone level

    3 to 6 months after starting

    Shows where the prescribed regimen has landed. When in the dosing cycle to draw depends on the formulation, so ask your prescriber.

    Source: Endocrine Society 2018

  • Hematocrit

    3 to 6 months after starting, then every year

    Testosterone raises red-cell count. Above 54% the guideline says to stop therapy until it comes down.

    Source: Endocrine Society 2018

  • Follow-up visit

    3 to 12 months after starting, then every year

    Whether symptoms have responded, and whether there are side effects.

    Source: Endocrine Society 2018

  • PSA

    3 to 12 months after starting, then per standard screening guidance

    For men who chose prostate monitoring before starting.

    Source: Endocrine Society 2018

  • Estradiol

    When there is breast tenderness or enlargement

    Checked on symptoms, not on a schedule.

    Source: Testosterone therapy, done right

  • Lipids and blood pressure

    Periodically, typically at least once a year

    Cardiovascular risk is reviewed alongside the hormone.

    Source: Testosterone therapy, done right

If hematocrit is climbing, see high hematocrit on TRT. The Log dates these checkpoints from the day you started.

Bloods in an ED workup

The blood work is one step of five. It looks for treatable causes and for the conditions erectile trouble can be an early sign of.

  • Total testosterone, early morning

    Repeated if it comes back low.

    Source: The ED workup

  • HbA1c or fasting glucose

    The screen for prediabetes and diabetes.

    Source: The ED workup

  • Lipid panel

    Standard cardiovascular risk: total, LDL, HDL, triglycerides.

    Source: The ED workup

  • Thyroid or prolactin

    Added when the history or exam points that way, not for everyone.

    Source: The ED workup

The other four steps are in the ED workup, start to finish.

Sources & important note

Testosterone diagnosis and monitoring items are from Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744 (recommendations 1.1–1.4 and 2.3, and Table 9). Items marked with a library article repeat what that article publishes under its own sources.

General education, not medical advice. Dose targets and adjustments are left out on purpose: those belong to your prescriber.

49 articles, every claim graded4 private tools, nothing leaves your browserWe sell nothing: no supplements, no products. Every source is named and every referral fee disclosed. The standard →